| Followers | 843 |
| Posts | 123011 |
| Boards Moderated | 9 |
| Alias Born | 09/05/2002 |
Wednesday, March 04, 2020 9:16:37 AM
EOLS comments on ITC preliminary proceedings, which were completed yesterday and may have gone badly for EOLS/Daewoong, according to anecdotal information:
https://www.globenewswire.com/news-release/2020/03/04/1995161/0/en/Evolus-Provides-Update-on-International-Trade-Commission-ITC-Case.html
Note: The ITC action, brought by AGN/Medytox against EOLS/Daewoong, is separate from Medytox’s lawsuit against Daewoong in Korea.
https://www.globenewswire.com/news-release/2020/03/04/1995161/0/en/Evolus-Provides-Update-on-International-Trade-Commission-ITC-Case.html
Note: The ITC action, brought by AGN/Medytox against EOLS/Daewoong, is separate from Medytox’s lawsuit against Daewoong in Korea.
“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”
Recent EOLS News
- Regenerative Medicine's Newest Public Company Is Building Tissue, Not Replacing It • PR Newswire (US) • 05/22/2026 02:31:00 PM
- Regenerative Medicine's Newest Public Company Is Building Tissue, Not Replacing It • PR Newswire (Canada) • 05/22/2026 02:31:00 PM
- Evolus to Participate in The Jefferies Global Healthcare Conference • Business Wire • 05/19/2026 12:30:00 PM
- Evolus Announces Commercial Launch of Estyme® Injectable Hyaluronic Acid Gels in Europe • Business Wire • 05/11/2026 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/04/2026 09:00:45 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/04/2026 08:05:48 PM
- Evolus Reports First Quarter 2026 Financial Results; Company Delivers Second Consecutive Quarter of Positive Adjusted EBITDA and Reaffirms Full-Year Outlook • Business Wire • 05/04/2026 08:05:00 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/29/2026 01:28:28 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/29/2026 01:28:20 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/29/2026 01:26:12 PM
- Evolus to Report First Quarter Financial Results on May 4, 2026 • Business Wire • 04/14/2026 12:30:00 PM
- Telix Appoints David Gill as Non-Executive Director • GlobeNewswire Inc. • 04/01/2026 11:53:07 PM
- Evolus to Participate in the Needham 25th Annual Virtual Healthcare Conference • Business Wire • 03/31/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/20/2026 11:19:00 PM
- Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • Business Wire • 03/20/2026 08:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/13/2026 08:43:16 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 03/03/2026 10:08:29 PM
- Evolus Reports Fourth Quarter and Full-Year 2025 Financial Results; Delivers Sixth Consecutive Year of Double-Digit Growth and Expects Sustainable Profitability1 Beginning in 2026 • Business Wire • 03/03/2026 09:05:00 PM
- Evolus to Participate in The Leerink Partners Global Healthcare Conference • Business Wire • 02/25/2026 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/20/2026 01:57:48 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/20/2026 01:57:42 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/20/2026 01:57:37 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/20/2026 01:57:28 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/20/2026 01:57:23 AM
